Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

Mation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12588082	
	Filing Date		2007-06-20	
	First Named Inventor Jens F		Fogh	
	Art Unit		1652	
	Examiner Name Yong		g D. Pak	
	Attorney Docket Number	er	S2071-7038US	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document		Releva		Lines where ges or Relev	
	1	7232670		2007-06	i-19	D'Azzo et al.					
If you wis	h to ac	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite N	No Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	20040126370		2004-07	'-01	D'Azzo et al.					
If you wis	h to ac	dd additional U.S. Publ	ished Ap	plication	citation	ı n information p	please click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or V	vhere Rel	or Relevant	T5
	1	0067789	WO			2006-11-16	CSL Limited				
	2	02/099092	wo		A2	2002-12-12	HEMEBIOTECH A	'S			
	3	03/002731	WO		A1	2003-01-09	HEMEBIOTECH A	rs			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		12588082
Filing Date		2007-06-20
First Named Inventor Jens F		Fogh
Art Unit		1652
Examiner Name Yong		D. Pak
Attorney Docket Number		S2071-7038US

	4	03/066669	WO	A2	2003-08-14	MILLIPORE CORPORATION				
	5	05/073367	WO	A1	2005-08-11	ZYMENEX A/S				
	6	99/37325	WO		1999-07-29	HEMEBIOTECH A/S				
	7	99/64462	WO		1999-12-16	STATENS SERUM INSTITUT				
	8	05/094874	WO	A1	2005-10-13	ZYMENEX A/S				
If you wisl	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	1 Add	•		
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T 5			
	1	Steven J. SHIRE et al., "Challenges in the Development of High Protein Concentration Formulations", Journal of Pharmaceutical Sciences, Vol. 93, No.6, June 2004, pp. 1390 - 1402.								
	2	Thomas POHL, "(7) Concentration of Proteins and Removal of Solutes", METHODS IN ENZYMOLOGY, vol. 182, 1990, pp. 68-83.								
	3		Caroline SEVIN et al., "Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy", Human Molecular Genetics, 2006, Vol. 15, No.1, pp. 53-64.							
	4	William R. PEARSON et al., "Improved tools for biological sequence comparison", Proc Natl Acad Sci USA, Vol 85, pp 2444-2448, April 1988.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		12588082
Filing Date		2007-06-20
First Named Inventor Jens F		Fogh
Art Unit		1652
Examiner Name Yong		D. Pak
Attorney Docket Number		S2071-7038US

5	William R. PEARSON, "(5) Rapid and Sensitive Sequence Comparison with FASTP and FASTA", METHODS OF ENZYMOLOGY, vol. 183, 1990, pp. 63-98.	
6	Julie D. THOMPSON et al., CIUSTAI W: improving the sensitivy of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice", Nucleic Acids Research, 1994, vol. 22, no. 22, 4673-4680.	
7	Arvan I. FLUHARTY et al., "[58] Arylsulfatases A and B from Human liver", Meth. Enzymol. 50:537-547, 1978.	
8	Abdul WAHEED et al., "Phosphorylation and sulfation of arylsulfatase A accompanies biosynthesis of the enzyme in normal and carcinoma cell lines", Biochimica et Biophysica Acta 847 (1985) 53-6l.	
9	Thomas BRAULKE et al., "SULFATED OLIGOSACCHARIDES IN HUMAN LYSOSOMAL ENZYMES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 143, no. 1, 1987, pp. 178-185.	
10	Thomas BRAULKE et al., "Insulin-like Growth Factors I and II Stimulate Endocytosis but Do Not Affect Sorting of Lysosomal Enzymes in Human Fibroblasts", The Journal of Biological Chemistry, Vol. 265, No. 12, Issue of April 25, 1990,pp.6650-6655.	
11	Bernadette M. KELLY et al., "Presence of a lysosomal enzyme, arylsulfatase-A, in the prelysosome-endosome compartments of human cultured fibroblasts", European Journal of Cell Biology, 48, 71-78, 1989.	
12	Nathan N. ARONSON, JR et al., "Lysosomal degradation of Asn-linked glycoprotein", the FASEB Journal, Vol. 3, Dec 1989, pp.2615-2622.	
13	Oivind NILSSEN et al., "a-Mannosidosis: functional cloning of the lysosomal a-mannosidase cDNA and identification of a mutation in two affected siblings", Human Molecular Genetics, 1997, Vol 6 No 5, pp. 717-726.	
14	Yasufumi KANEDA et al., "Regional assignment of five genes on human chromosome 19", CHROMOSOMA (BerJ) (1987) 95:8-12.	
15	Hilde Monica Frostad RIISE et al., "Genomic Strucutre of the Human Lysosomal a-Mannosidase Gene (MANB) GENOMICS 42, 200-207 (1997).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		12588082
Filing Date		2007-06-20
First Named Inventor Jens		Fogh
Art Unit		1652
Examiner Name Yong		D. Pak
Attorney Docket Number		S2071-7038US

	16	Yung-Feng LIAO et al., "Cloning, Expression, Purification and Characterization of the Human Broad Specificity Lysosomal Acid a-Mannosidase", The Journal of Biological Chemistry, Vol. 271, No. 45, Issue of November 8, 1996, pp. 28348-28358.							
	17	OF T	Vicki L. NEBES et al., "HUMAN LYSOSOMAL ALPHA-MANNOSIDASE: ISOLATION AND NUCLEOTIDE SEQUENCE OF THE FULL-LENGTH cDNA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 200, No.1, 1994, pp. 239-245.						
	18		P. N. MEISSNER et al., "Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria", European Journal of Clinical Investigation (1986) 16 257-261.						
	19		Richard J. HIFT et al., "Variegate porphyria in South Africa, 1688-1996 - new developments in an old disease", S. Afr. Med. J., Vol. 87, No.6, June 1997, pp. 722-731.						
	20	Peter MEISSNER et al., "Allosteric Inhibition of Human Lymphoblast and Purified Porphobilinogen Deaminase by Protoporphyrinogen and Coproporphyrinogen", J. Clin. Invest., 1993, vol. 91,1436-1444.							
	21	James AUSTIN et al., "Abnormal Sulphatase Activities in Two Human Diseases (Metachromatic Leucodystrophy and Gargoylism)", Biochem. J. (1964),93, 15c-17c.							
If you wis	h to ac	dd add	litional non-patent literature document citation information pleas	se click the Add b	utton Add				
			EXAMINER SIGNATURE						
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.									